Adenoviral Delivery of Human and Viral IL-10 in Murine Sepsis

J Immunol July 15, 2001, 167 (2) 1053-1059

Posted: 15 Apr 2019

Date Written: July 15, 2001


Adenovirus (Ad) gene therapy has been proposed as a drug-delivery system for the targeted administration of protein-based therapies, including growth factors and biological response modifiers. However, inflammation associated with Ad transduction has raised concern about its safety and efficacy in acute inflammatory diseases. In the present report, intratracheal and i.v. administration of a first-generation adenoviral recombinant (E1,E3 deleted) either containing an empty cassette or expressing the anti-inflammatory cytokines viral or human IL-10 (IL-10) was administered to mice subjected to zymosan-induced multisystem organ failure or to acute necrotizing pancreatitis. Pretreatment of mice with the intratracheal instillation of Ad expressing human IL-10 or viral IL-10 reduced weight loss, attenuated the proinflammatory cytokine response, and reduced mortality in the zymosan-induced model, whereas pretreatment with a control adenoviral recombinant did not significantly exacerbate the response. Pretreatment of mice with pancreatitis using adenoviral vectors expressing IL-10 significantly reduced the degree of pancreatic and liver injury and liver inflammation when administered systemically, but not intratracheally. We conclude that adenoviral vectors can be administered prophylactically in acute inflammatory syndromes, and expression of the anti-inflammatory protein IL-10 can be used to suppress the underlying inflammatory process.

Keywords: gene therapy, inflammation, IL-10

Suggested Citation

Shinoda, Jeremy, Adenoviral Delivery of Human and Viral IL-10 in Murine Sepsis (July 15, 2001). J Immunol July 15, 2001, 167 (2) 1053-1059, Available at SSRN:

Jeremy Shinoda (Contact Author)

Cordant Health Solutions ( email )

United States


Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Abstract Views
PlumX Metrics